The primary objectives of this investigational device exemption (IDE) clinical investigation are to (1) assess the safety of the investigational Jarvik 2015 through the evaluation of reported serious adverse events (SAEs) while on ventricular assist device (VAD) support up to the first 180 days post-implant and (2) explore the probable benefit of the investigational Jarvik 2015 by evaluating overall survival in the absence of severe neurologic impairment.